SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Pfizer inches up on launching new medication for migraine treatment

18 Nov 2025 Evaluate

Pfizer is currently trading at Rs. 5064.00, up by 5.75 points or 0.11% from its previous closing of Rs. 5058.25 on the BSE.

The scrip opened at Rs. 5055.00 and has touched a high and low of Rs. 5069.00 and Rs. 5049.55 respectively. So far 33 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 5987.65 on 16-Jun-2025 and a 52 week low of Rs. 3742.90 on 07-Apr-2025.

Last one week high and low of the scrip stood at Rs. 5329.05 and Rs. 4980.15 respectively. The current market cap of the company is Rs. 23166.65 crore.

The promoters holding in the company stood at 63.92%, while Institutions and Non-Institutions held 19.70% and 16.37% respectively.

Pfizer has launched a new medication for migraine treatment. The company has introduced Rimegepant ODT in India for adults with a previous insufficient response to triptan, the usual drugs for treating migraine.

The new medication delivers rapid and sustained pain relief lasting up to 48 hours post-treatment, while not associated with the risk of medication overuse headaches. Rimegepant will be available in a 75 mg orally disintegrating tablet (ODT) form, designed for convenient administration without the need for water.

Pfizer is engaged in manufacturing, marketing, trading and export of pharmaceutical products.

Pfizer Share Price

4891.60 -62.45 (-1.26%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×